These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31871092)

  • 1. Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by
    Abdullahi ST; Soyinka JO; Olagunju A; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Winterberg M; Tarning J; Owen A; Khoo S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
    Abdullahi ST; Olagunju A; Soyinka JO; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Owen A; Khoo S
    Br J Clin Pharmacol; 2019 Mar; 85(3):540-550. PubMed ID: 30471138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers.
    Abdullahi ST; Soyinka JO; Olagunju A; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Winterberg M; Tarning J; Owen A; Khoo S
    J Clin Pharmacol; 2020 Mar; 60(3):351-360. PubMed ID: 31549442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
    Adegbola AJ; Rana A; Adeagbo BA; Bolarinwa RA; Olagunju AE; Siccardi M; Owen A; Bolaji OO
    Pharmacogenet Genomics; 2020 Jul; 30(5):96-106. PubMed ID: 32209837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
    J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
    Huang L; Carey V; Lindsey JC; Marzan F; Gingrich D; Graham B; Barlow-Mosha L; Ssemambo PK; Kamthunzi P; Nachman S; Parikh S; Aweeka FT;
    PLoS One; 2017; 12(10):e0186589. PubMed ID: 29065172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
    Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
    Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
    Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
    Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C
    OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
    Chou M; Bertrand J; Segeral O; Verstuyft C; Borand L; Comets E; Le Tiec C; Becquemont L; Ouk V; Mentre F; Taburet AM
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4432-9. PubMed ID: 20696882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity.
    Singh H; Lata S; Dhole TN; Gangakhedkar RR
    Mol Genet Genomic Med; 2019 Apr; 7(4):e00598. PubMed ID: 30864294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Okaba-Kayom V; Mayanja-Kizza H; Katabira E; Hanpithakpong W; Pakker N; Dorlo TP; Tarning J; Lindegardh N; de Vries PJ; Back D; Khoo S; Merry C
    J Antimicrob Chemother; 2012 May; 67(5):1217-23. PubMed ID: 22316571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of the antimalarial combination therapy artemether-lumefantrine in normal-weight, overweight and obese healthy male adults.
    Sugiarto SR; Page-Sharp M; Drinkwater JJ; Davis WA; Salman S; Davis TME
    Int J Antimicrob Agents; 2022 Jan; 59(1):106482. PubMed ID: 34818520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.
    Oluka MN; Okalebo FA; Guantai AN; McClelland RS; Graham SM
    AIDS Res Ther; 2015; 12():10. PubMed ID: 25878720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
    Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
    Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.